Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations

Patients with cancer and advanced hepatic impairment (HI) (i.e., moderate and severe impairment) are often excluded from first‐in‐patient, phase II, and phase III studies. Thus, dose recommendations for this subgroup of patients are often derived using a combination of dedicated phase I studies cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Derek Z., Alhadab, Ali, Parivar, Kourosh, Wang, Diane D., Elmeliegy, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540487/
https://www.ncbi.nlm.nih.gov/pubmed/34870845
http://dx.doi.org/10.1002/cpt.2505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540487/
https://www.ncbi.nlm.nih.gov/pubmed/34870845
http://dx.doi.org/10.1002/cpt.2505

Ejemplares similares